{
  "paper_metadata": {
    "pmid": "34234458",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on a BRCA2 variant associated with a patient diagnosed with combined hepatocellular-cholangiocarcinoma."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.97G>T",
      "protein_notation": "p.E33*",
      "genomic_position": "Chr 13:32893243",
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 1,
        "demographics": "71-year-old male",
        "phenotype": "metastatic combined hepatocellular-cholangiocarcinoma"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 1,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 71,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "metastatic combined hepatocellular-cholangiocarcinoma",
          "evidence_sentence": "A genomic analysis revealed the presence of genome-wide LOH (gLOH), contributing to the 'BRCAness' phenotype and indicating a potential benefit from PARP inhibitor."
        }
      ],
      "functional_data": {
        "summary": "The BRCA2 mutation is associated with sensitivity to PARP inhibitors.",
        "assays": [
          "Sanger sequencing",
          "comprehensive genomic profiling"
        ]
      },
      "segregation_data": "Not applicable as only one patient is reported.",
      "population_frequency": null,
      "evidence_level": "moderate",
      "source_location": "Table 1",
      "additional_notes": "The mutation was not found in the patient's peripheral blood mononuclear cell sample, indicating it is not a germline mutation.",
      "key_quotes": [
        "Loss of heterozygosity of BRCA2 E33* mutations can result in the biallelic inactivation of BRCA2, which would indicate sensitivity to poly ADP-ribose polymerase (PARP) inhibitors."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 1",
      "table_caption": "Clinically Relevant Single Nucleotide Variants Detected in Patient\u2019s Liver Tumor Biopsy",
      "variants_extracted": 1
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "The extraction was straightforward as the paper provided clear information on the BRCA2 variant."
  }
}